<DOC>
	<DOCNO>NCT00246012</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness intetumumab , alone combination dacarbazine , patient stage 4 melanoma .</brief_summary>
	<brief_title>A Safety Efficacy Study Intetumumab , Alone Combination With Dacarbazine , Participants With Stage 4 Melanoma</brief_title>
	<detailed_description>This Phase 1/2 , multi-center , randomize ( study medication assign chance ) study . This study conduct 2 Phases ( Phase 1 Phase 2 ) . Phase 1 study non-randomized , open-label ( people know identity intervention ) dose-escalation phase . It include screening period treatment period , consist 2 part ( Part 1 Part 2 ) . In Part 1 , participant receive 1 3 single dose level intetumumab [ 3 milligram per kilogram ( mg/kg ) , 5 mg/kg 10 mg/kg ] . Part 2 include 2 dose cohort : dacarbazine plus intetumumab ( 5 mg/kg ) dacarbazine plus intetumumab ( 10 mg/kg ) . Phase 2 study randomize , blind ( neither physician participant know intervention participant receive ) control ( inactive substance medication compare study medication test whether medication real effect clinical study ) . This phase study include screen period , treatment period ( 8 cycle treatment every cycle 3 week ) follow-up period ( 24 week ) . During treatment period , participant randomly assign 1 4 treatment group , Group 1 : dacarbazine plus placebo , Group 2 : intetumumab ( 5 mg/kg ) , Group 3 : intetumumab ( 10 mg/kg ) Group 4 : dacarbazine plus intetumumab . Randomization base site metastasis Eastern Cooperative Oncology Group performance status Baseline . Single-medication intetumumab treatment group open-label , dacarbazine plus intetumumab placebo group blind . The total duration Phase 2 study 52 week 76 week case extend dosing ( extended administration [ 8 additional cycle ] assign treatment allow participant respond therapy stable disease well ) . Participants assess incidence dose limit toxicity , pharmacokinetics tumor response . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically confirm melanoma include ocular mucosal Documented AJCC ( American Joint Committee Cancer ) Stage 3 unresectable Stage 4 melanoma ( Phase 1 ) ; AJCC Stage 4 melanoma ( Phase 2 ) Radiographically measurable disease measurable skin lesion Prior chemotherapy metastatic melanoma allow Phase 1 , previously untreated melanoma chemotherapy allow Phase 2 Agrees protocoldefined use effective contraception History receive murine human/murine recombination product human αν integrins Known human immunodeficiency virus ( HIV ) positivity clinically important active infection Presence bone metastases malignant effusion ( nonmeasurable lesion ) central nervous system metastases Prior radiation target lesion Concurrent immunotherapy , biotherapy , radiotherapy , chemotherapy , investigational therapy therapeutic use anticoagulation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Melanoma</keyword>
	<keyword>Neoplasm</keyword>
	<keyword>CNTO 95</keyword>
	<keyword>Dacarbazine</keyword>
	<keyword>Intetumumab</keyword>
</DOC>